One in Ten Pills Is a Lie

WHO estimates 1 in 10 medical products in low- and middle-income countries is substandard or falsified. Falsified antimalarials alone kill an estimated 267,000 people per year in sub-Saharan Africa; falsified antibiotics drive antimicrobial resistance. Quality verification requires HPLC or mass spectrometry in centralized laboratories, but substandard products enter fragmented distribution networks and reach patients at peripheral health facilities and open-air markets where no testing infrastructure exists. No affordable, reliable field test can verify both drug identity and approximate dosage at the point where patients actually receive medicines.

Beyond direct mortality, substandard medicines undermine trust in health systems and accelerate AMR by exposing pathogens to sub-therapeutic drug concentrations. The WHO Global Surveillance System documents ~150,000 reports of substandard/falsified products since 2013. The economic burden in sub-Saharan Africa alone exceeds $12 billion/year in wasted drug purchases and downstream health costs.

Packaging analysis (holograms, barcodes) is easily counterfeited. The Notre Dame Paper Analytical Device (PAD) uses colorimetric chemistry for screening at ~$1/test but only provides binary pass/fail for a limited set of active ingredients — it cannot detect incorrect dosage or degraded formulations. Portable Raman and NIR spectroscopy (TruScan, GPHF Minilab) costs $15,000–$45,000 per unit, requires training, and has variable accuracy with complex formulations. Blockchain track-and-trace systems (mPedigree) verify packaging via SMS but cannot verify actual drug content. None achieves the required combination: <$500 device cost, <$5/test, semi-quantitative dosage verification, usable by non-specialist health workers, covering the 50 most commonly falsified essential medicines.

A handheld device under $500 that verifies both identity and approximate concentration of active pharmaceutical ingredients across the most commonly falsified essential medicines. This likely requires advances in miniaturized spectroscopy (SERS, portable Raman, or paper-based ELISA) combined with ML spectral libraries trained on local formulations. Alternatively, paper-based lateral flow assays that go beyond binary pass/fail to provide semi-quantitative dosage estimation for key drug classes.

A team could build and test a low-cost SERS substrate optimized for detecting one commonly falsified drug class (e.g., artemisinin-based antimalarials) at semi-quantitative concentrations. Alternatively, a team could benchmark existing portable spectroscopy tools against reference HPLC results for a panel of medicines common in LMICs, quantifying the accuracy-cost frontier. Analytical chemistry, spectroscopy, and global health skills apply.